Cargando…

Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up study

PURPOSE: The primary purpose of this study was to evaluate the proportion of psoriatic arthritis (PsA) patients maintaining clinical remission after adalimumab (ADA) dose reduction compared with patients with rheumatoid arthritis. Secondary purposes include evaluating the proportion of PsA patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cantini, Fabrizio, Niccoli, Laura, Cassarà, Emanuele, Kaloudi, Olga, Nannini, Carlotta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3421476/ https://www.ncbi.nlm.nih.gov/pubmed/22904612 http://dx.doi.org/10.2147/BTT.S31145

Ejemplares similares

Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study
por: Cantini, Fabrizio, et al.
Publicado: (2013)

Systemic autoimmune disease in asbestosis rapidly responding to anti-interleukin-1beta antibody canakinumab: a case report
por: Niccoli, Laura, et al.
Publicado: (2015)

Efficacy of infliximab in refractory Behçet’s disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients
por: Cantini, Fabrizio, et al.
Publicado: (2012)

Bioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis
por: Cantini, Fabrizio, et al.
Publicado: (2009)

Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables
por: Niccoli, Laura, et al.
Publicado: (2018)

Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics
por: Cantini, Fabrizio, et al.
Publicado: (2017)

Effectiveness of Adalimumab for the Treatment of Psoriatic Arthritis: An Italian Real-Life Retrospective Study
por: D'Angelo, Salvatore, et al.
Publicado: (2019)

The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis
por: Tanaka, Yoshiya, et al.
Publicado: (2019)

Demographics and clinical characteristics associated with sustained remission and continuation of sustained remission in patients with rheumatoid arthritis treated with adalimumab
por: Kimura, Noriko, et al.
Publicado: (2019)

Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)
por: Mease, P J, et al.
Publicado: (2008)

Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients
por: Lubrano, Ennio, et al.
Publicado: (2019)

Psoriatic Arthritis That Responded Dramatically When Infliximab Was Switched to Adalimumab
por: Ohshima, Yuichiro, et al.
Publicado: (2013)

Effectiveness of dose reduction of etanercept and adalimumab in patients with rheumatoid arthritis
por: Martínez-Pérez, Rosalía, et al.
Publicado: (2011)

Long-term treatment with adalimumab in psoriatic arthritis: serum adalimumab concentration, immunogenicity and the link with clinical response
por: Chimenti, Maria Sole, et al.
Publicado: (2016)

Remission in psoriatic arthritis: is it possible and how can it be predicted?
por: Saber, Tajvur P, et al.
Publicado: (2010)

Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity
por: Landewé, Robert, et al.
Publicado: (2019)

Brain abscess in a patient with psoriatic arthritis treated with adalimumab: A case report
por: Lo, Yu-Pei, et al.
Publicado: (2020)

Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis
por: Wcisło-Dziadecka, Dominika, et al.
Publicado: (2020)

The influence of adalimumab treatment on the systemic gene expression in patients with psoriatic arthritis – preliminary report
por: Krawczyk, Agata, et al.
Publicado: (2021)

Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease
por: Wu, Kai-Chun, et al.
Publicado: (2016)

Efficacy of Switching to Adalimumab for Maintenance of Remission Following Induction Therapy with Tacrolimus in Patients with Ulcerative Colitis
por: Numa, Keijiro, et al.
Publicado: (2023)

Demographic and Clinical Factors Associated with Patient-Reported Remission in Psoriatic Arthritis
por: Gondo, George, et al.
Publicado: (2022)

Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis
por: Westhovens, Rene, et al.
Publicado: (2015)

Evaluation of Clinical and Ultrasonographic Parameters in Psoriatic Arthritis Patients Treated with Adalimumab: A Retrospective Study
por: Teoli, M., et al.
Publicado: (2012)

Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study
por: Emery, Paul, et al.
Publicado: (2020)

Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction
por: Landewé, Robert BM, et al.
Publicado: (2020)

Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions
por: Van den Bosch, F, et al.
Publicado: (2010)

Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison
por: Strand, Vibeke, et al.
Publicado: (2017)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
por: Gladman, Dafna D., et al.
Publicado: (2022)

Remission of Psoriasis and Psoriatic Arthritis During Bevacizumab Therapy for Renal Cell Cancer
por: Datta-Mitra, Ananaya, et al.
Publicado: (2014)

Antibodies to Infliximab and Adalimumab in Patients with Rheumatoid Arthritis in Clinical Remission: A Cross-Sectional Study
por: Eng, Grith P., et al.
Publicado: (2015)

Real-world evidence of the impact of adalimumab on work productivity and sleep measures in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
por: Tektonidou, Maria G., et al.
Publicado: (2020)

Correction: Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction
Publicado: (2020)

Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy
por: Rudwaleit, Martin, et al.
Publicado: (2010)

Minimal disease activity is a stable measure of therapeutic response in psoriatic arthritis patients receiving treatment with adalimumab
por: Behrens, Frank, et al.
Publicado: (2018)

Real-World Postmarketing Study of the Impact of Adalimumab Treatment on Work Productivity and Activity Impairment in Patients with Psoriatic Arthritis
por: Nakagawa, Hidemi, et al.
Publicado: (2019)

Patient’s perspective of sustained remission in rheumatoid arthritis
por: Contreras-Yáñez, Irazú, et al.
Publicado: (2017)

Prevalence and predictors for sustained remission in rheumatoid arthritis
por: Sung, Yoon-Kyoung, et al.
Publicado: (2019)

Remission of psoriasis and psoriatic arthritis during bevacizumab therapy for renal cell cancer: Erratum
por: Lahiri, Koushik
Publicado: (2015)

A Machine Learning Approach to Predict Remission in Patients With Psoriatic Arthritis on Treatment With Secukinumab
por: Venerito, Vincenzo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p0o4mqvnrhl0greakl5apl8512